Polish founder builds emotion-enabled voice device for laryngectomees after cancer

When Konrad Zieliński was studying at the University of Warsaw, cancer took his voice. He explained to TechCrunch that people facing this challenge have historically turned to two options: portable speaking devices that produce monotone, synthetic-sounding output, or surgically implanted voice replacements that demand regular upkeep to avoid medical complications.

Zieliński pursued doctoral research in bionic systems designed for laryngectomees—individuals whose larynxes have been surgically removed. During his research, he became determined to engineer a non-surgical alternative that would restore the ability to speak with natural emotion, to laugh, to raise one's voice, and even to sing.

Uhura Bionics, founded in 2023, represents Zieliński's answer to this challenge. The company has earned a spot among TechCrunch Disrupt 2026's Battlefield 200, a curated selection of emerging enterprises preparing to debut their innovations at the upcoming conference. Uhura manufactures two wearable systems: a standard-tier device and a premium model branded Whitney, honoring the legendary vocalist Whitney Houston.

Zieliński envisions his creation functioning as a parallel to corrective eyewear. "I'm satisfied with what I've built because you added the emotional layer," he remarked through the device itself, which demonstrates noticeable inflection despite a subtle electronic quality.

The company's roadmap includes introducing higher-frequency voice profiles suited for women and customization tools enabling individual acoustic signatures rather than uniform output across all users.

Currently, Uhura positions its offerings as wellness products, requiring consumers to cover expenses directly: $500 for the basic unit and $1,500 for Whitney. The organization is pursuing Class I medical device designation—the lowest-risk tier—from European regulators and subsequently from U.S. authorities. This regulatory pathway would unlock partial insurance reimbursement eligibility.

Zieliński calculates the addressable market for laryngectomee devices at approximately $2 billion, though he believes expansion into other speech impairment categories could substantially enlarge this figure.

The voice restoration sector includes established competitors such as Atos Medical, a device manufacturer with existing offerings, alongside emerging players like Laronix. Yet Zieliński remains convinced Whitney will appeal strongly to fellow laryngectomees. Beyond his TechCrunch Disrupt presentation, he intends to perform onstage at SF Tech Week in October, singing with Whitney's assistance to demonstrate its capabilities.